



Cost Incurred to Treat a Patient (Lifetime)



IVUS, Intravascular ultrasound; PCI, percutaneous coronary intervention

§ At 3 years, TVF occurred in 47 patients (6.6%) in the IVUS-guided group and in 76 patients (10.7%) in the angiography-guided group (p = 0.01)

- Fujimura T, et al. Stent Expansion Indexes to Predict Clinical Outcomes: An IVUS Substudy From ADAPT-DES. JACC Cardiovasc Interv. 2021;14(15): 1639-50. 1.
- Gao XF, et al. 3-Year Outcomes of the ULTIMATE Trial Comparing Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation. JACC Cardiovasc Interv. 2021;14(3): 247-57. 2.
- 3. Banning A, et al. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. Eur Heart J. 2022;43(13): 1307–16.
- Albertini A, et al. Understanding the economic impact of intravascular ultrasound (IVUS). Eur J Health Econ. 2016;17, 185–93. 4.
- Ahn JM, et al. Meta-analysis of outcomes after intravascular ultrasound-guided versus angiography-guided drug-eluting stent implantation in 26,503 patients enrolled in three randomized trials and 14 observational studies. Am J Cardiol. 5. 2014 ;15;113(8): 1338-47.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

IC-1365203-AA © 2022 Boston Scientific Corporation or its affiliates. All rights reserved.